Avinger (NASDAQ:AVGR – Get Free Report) and Titan Medical (NASDAQ:TMDIF – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
18.3% of Avinger shares are owned by institutional investors. Comparatively, 0.0% of Titan Medical shares are owned by institutional investors. 43.7% of Avinger shares are owned by company insiders. Comparatively, 0.0% of Titan Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Avinger and Titan Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avinger | -261.06% | -5,527.11% | -123.25% |
| Titan Medical | N/A | -82.31% | -51.47% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avinger | 0 | 0 | 1 | 0 | 3.00 |
| Titan Medical | 0 | 0 | 0 | 0 | 0.00 |
Avinger presently has a consensus target price of $5.00, indicating a potential upside of 244.83%. Given Avinger’s stronger consensus rating and higher possible upside, analysts plainly believe Avinger is more favorable than Titan Medical.
Valuation & Earnings
This table compares Avinger and Titan Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avinger | $7.26 million | 0.66 | -$18.32 million | ($11.06) | -0.13 |
| Titan Medical | $17.63 million | 2.59 | $6.95 million | $0.05 | 8.00 |
Titan Medical has higher revenue and earnings than Avinger. Avinger is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Avinger has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Titan Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Summary
Titan Medical beats Avinger on 8 of the 14 factors compared between the two stocks.
About Avinger
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.
About Titan Medical
Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada.
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.
